Skip to content

Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

Nterest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05062655
Acronym
ICOCON
Enrollment
82
Registered
2021-09-30
Start date
2021-11-08
Completion date
2022-11-12
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospitalized Patient

Keywords

Medication reconciliation, Continuity, Town-hospital network

Brief summary

From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient. Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity. The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management. This new organisation is part of the policy of continuous improvement of the quality and safety of care

Interventions

OTHERDrug reconciliation

Drug reconciliation information transmission to pharmacist interview with the patient

Sponsors

Centre Hospitalier le Mans
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* hospitalized patient * Patient with a drug treatment with a particular mode of supply * Paediatric patient or an adult patient. * First inpatient stay over the inclusion period from late 2021 to late 2022

Exclusion criteria

* Patient under curatorship or guardianship * Patient residing abroad * No free, informed and written consent obtained

Design outcomes

Primary

MeasureTime frameDescription
Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment1 month after inclusionValue of coordinated pathway is evaluated by number of days of treatment interruption between patient discharge and provision of treatment to the patient

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026